Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Peanut Allergy Treatment Market Size And Revenue Outlook Through 2030
The peanut allergy treatment market has expanded quickly in recent years. Its valuation is set to increase from $0.5 billion in 2025 to $0.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.8%. Historically, this growth can be linked to the increasing occurrence of peanut allergies in children, the insufficient efficacy of avoidance-only management, a rise in food allergy diagnoses, a significant dependence on epinephrine for emergency care, and heightened awareness among medical professionals.
The peanut allergy treatment market size is anticipated to experience robust expansion over the next few years. It is predicted to reach $0.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.7%. This growth during the forecast period is fueled by advancements in immunotherapy technologies, an increase in approvals for disease-modifying treatments, a rising demand for preventive allergy care, the expansion of biologics targeting allergic pathways, and growing investment in food allergy research. Significant trends anticipated include the increasing adoption of oral immunotherapy for peanut desensitization, a growing use of epicutaneous immunotherapy patches, greater integration of biologic therapies in allergy treatment, the expansion of pediatric-focused peanut allergy treatments, and a stronger emphasis on long-term allergy management solutions.
Get A Free Sample Report With In-Depth Market Insights:
Peanut Allergy Treatment Market Growth Factors Behind Sustained Expansion
The future expansion of the peanut allergy treatment market is expected to be propelled by investments in research and development for allergy treatments. Research and development (R&D) investment refers to the financial resources allocated by companies, organizations, or governments towards activities aimed at innovation, product development, and technological advancement. This investment in R&D for allergy treatments is crucial for advancing peanut allergy therapies, as it fosters the creation of innovative immunotherapies and desensitization techniques. These innovations aim to reduce allergic reactions and improve the quality of life for those affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding is part of a broader $66 million round aimed at developing Aravax’s innovative immunotherapy, PVX108. This initiative has secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), underscoring its potential impact on public health worldwide. Therefore, investment in research and development of allergy treatments is driving the growth of the peanut allergy treatment market.
Peanut Allergy Treatment Market Breakdown By Product Type And Application
The peanut allergy treatment market covered in this report is segmented –
1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
Subsegments:
1) By Antihistamines: Oral Antihistamines, Topical Antihistamines
2) By Immunotherapies: Oral Immunotherapy (OIT), Sublingual Immunotherapy (SLIT), Epicutaneous Immunotherapy (EPIT)
3) By Epinephrine: Epinephrine Auto-Injectors, Epinephrine Inhalers
4) By Other Drug Classes: Leukotriene Receptor Antagonists, Monoclonal Antibodies, Corticosteroids
Peanut Allergy Treatment Market Industry Trends Fueling Future Revenue Growth
Leading companies in the peanut allergy treatment market are prioritizing the development of biologic therapies, such as anti-IgE monoclonal antibodies, to provide more targeted and effective solutions for managing peanut allergies, with the goal of improving patient outcomes and quality of life. These anti-IgE monoclonal antibodies are therapeutic agents designed to specifically target and neutralize immunoglobulin E (IgE) antibodies in the body. For instance, in February 2024, Novartis Pharmaceuticals Corporation, a Switzerland-based pharmaceutical company, obtained approval from the Food and Drug Administration (FDA) for Xolair (omalizumab). This medication is designed to lessen allergic reactions, including anaphylaxis, in patients aged 1 year and above who have IgE-mediated food allergies. The approval was granted based on data from the NIH-sponsored Phase III OUtMATCH study, which indicated significant improvements in food allergy tolerance among patients treated with Xolair when compared to those given a placebo.
Peanut Allergy Treatment Market Company Landscape And Competitive Strategy
Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.
View The Full Peanut Allergy Treatment Market Report:
Peanut Allergy Treatment Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the peanut allergy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
